
- /
- Supported exchanges
- / US
- / MIST.NASDAQ
Milestone Pharmaceuticals Inc (MIST NASDAQ) stock market data APIs
Milestone Pharmaceuticals Inc Financial Data Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Milestone Pharmaceuticals Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Milestone Pharmaceuticals Inc data using free add-ons & libraries
Get Milestone Pharmaceuticals Inc Fundamental Data
Milestone Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -54 912 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Milestone Pharmaceuticals Inc News

Milestone Pharmaceuticals GAAP EPS of -$0.20 misses by $0.02
* Milestone Pharmaceuticals press release [https://seekingalpha.com/pr/20197244-milestone-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides] (NASDAQ:MIST [https://seekingalp...


Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDA...

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.63%
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Telecoms, Healthcare and Financials sectors led shares lower. At the close in NYSE, the Dow Jones Industrial Avera...

Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain inve...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.